Physicochemical compatibility and stability of urapidil-propofol admixtures during simulated Y-site Administration
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background/Objectives
Urapidil with propofol is clinically efficient against elevated blood pressure during sedation. However, their physicochemical compatibility and emulsion stability upon continuous infusion remain unclear. This study aimed to evaluate different mixing ratios and diluents, thereby proving the safety limits for their co-administration.
Methods
Urapidil solutions prepared with either sodium chloride (NS) or glucose injection (GS), and emulsified with propofol at different ratios (v/v), were stored for 12 h. Physical compatibility was assessed by visual inspection, pH, osmolality, mean droplet diameter (MDD), polydispersity index (PDI), zeta potential, and percentage of fat globules larger than 5 μm (PFAT 5 ). Chemical stability was quantified using high-performance liquid chromatography.
Results
pH and osmolality stabilized. Urapidil hydrochloride and propofol contents remained pure at > 95%, MDD was < 500 nm, and PDI was < 0.2. Urapidil proportion in NS was significantly negatively correlated with the zeta potential. PFAT 5 was > 0.05% after 2‒8 h. In contrast, in GS at a 1:2 ratio, PFAT 5 remained < 0.05%, which increased slightly in the 1:1 group at 8 h. PFAT 5 stabilized in the high-propofol group (10:1) under all conditions.
Conclusions
The chemical compatibility of the admixture was acceptable after 12 h of storage. However, physical compatibility was influenced by the mixing ratio, diluent type, and storage time. For clinical Y-site co-administration, a 10:1 mixing ratio or dilution in 5% GS is recommended. Enhanced proportions must be mixed with NS, while continuous infusion time must be < 2 h to mitigate fat embolism risk.
